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Background
Local anesthetic systemic toxicity (LAST), including cardiovascular (CV) and central nervous system (CNS) complications, is a rare but devastating complication of regional anesthesia. Soon after the first successful use of cocaine as a local anesthetic (LA) in the late 19th century, there were case reports describing systemic toxicity and recommendations for its prevention. 1, 2 Arguably, LAST has been the major impetus for the development of newer (and safer) LA agents throughout the 20th century. 3 Until the last decade, there were few options for treatment of LAST beyond a prolonged cardiopulmonary resuscitation (CPR). 4 However, the recent successful use of intravenous lipid emulsions in severe LAST has dramatically changed the clinical management of this dreaded complication.
Major organizations such as the American Society of Regional Anesthesia and the Association of Anaesthetists of Great Britain and
Ireland have incorporated the use of lipid emulsions as a first-line medication in LAST. 6, 7 Nevertheless, a number of controversies remain about their role. In this chapter, we will first provide short background information about the status of the use of lipid emulsions in LAST. We will then review 2 controversial questions: (1) are lipid emulsions effective in systemic toxicity secondary to all LAs; and (2) how do lipid emulsions fit in the advanced cardiac life support (ACLS) protocol for cardiac arrest due to LAST?
Mechanism of Action of Lipid Emulsion in LAST
The exact mechanism of action of lipid emulsions in the treatment of LAST is not completely understood. Several theories are proposed, among which the ''lipid sink theory'' is the simplest and the most widely known. This theory postulates that the administration of a lipid emulsion provides an alternative binding surface and therefore acts as a ''sink'' for the fraction of LA molecules in their lipophilic state. In this regard, lipid emulsion is not an antidote for a specific LA, but rather a potential nonspecific treatment method that relies on physicochemical principles. Lipid emulsion has been successfully used in treating toxicity secondary to a diverse group of lipophilic drugs including verapamil, atenolol, haloperidol, bupropion, lamotrigine, sertraline, and quetiapine. [8] [9] [10] This observation supports a nonspecific mechanism of action. Creating a lipid sink might not be the only mechanism of action for lipid emulsions in reversing clinical features of LAST. In some experimental models, in vivo action of lipid emulsions occur more rapidly than that could only be attributed to a lipid sink phenomenon. 11 Intravenous administration of lipid emulsion might also (i) increase the intracellular myocardial fatty acid content, (ii) augment the mitochondrial fatty acid metabolism, and (iii) replenish adenosine triphosphate stores. Infused lipid emulsion might act as a direct inotrope by increasing intracellular calcium concentration in the myocardium.
Lipid Emulsions and the Current Guidelines for Management of LAST
Use of lipid emulsion is now a component of several professional guidelines and practice advisories for the management of LAST. 6, 7 The usual recommended dose is 1.5 ml/kg bolus followed by an infusion of 0.25 ml/kg/min (calculated for ideal body weight) of a 20% lipid emulsion (eg, 20% Intralipid, Fresenius Kabi, Uppsala, Sweden). If hemodynamic stability is not achieved, repeating the bolus dose (up to a total of 3 boluses, 3 to 5 min apart), followed by increasing the infusion (to 0.5 ml/kg/min) is recommended. The accepted allowable maximum dose is 10 to 12 ml/kg, given over 30 minutes.
Does the Choice of Lipid Emulsion Matter?
Intravenous lipid emulsions vary in terms of their fatty acid composition. Intralipid, a soy-based long-chain fatty acid emulsion, was used in majority of the studies published on lipid rescue in LAST. In contrast, at least 1 case report 12 and 1 animal study 13 reported the use of lipid emulsions containing medium-chain fatty acids. From a physicochemical perspective, lipid emulsions with long chain fatty acids seem to have an advantage. In an in vitro study, Mazoit et al 14 compared Intralipid and Medialipide (B. Braun, Boulogne, France) in their binding capacity for racemic bupivacaine, levobupivacaine, and ropivacaine. Intralipid was 2.5 times more efficacious than Medialipide in its buffering property for these LAs. It is unclear whether this might translate to a difference in clinical efficacy. Notably, they also found that low pH reduced lipid binding of LAs.
Safety of Intravenous Administration of Lipid Emulsion: Intravenous administration of lipid emulsions may interfere with the clinical laboratory measurements. Total hemoglobin and methhemoglobin measurements are falsely elevated in the presence of Intralipid in blood, presumably due to an interference with spectrophotometric assessment. 15, 16 Similarly, electrolytes, base excess, and hemoglobin could not be determined after the intravenous administration of lipid emulsion in a recent case report. 17 Side effects of lipid emulsions as a part of parenteral nutrition (eg, microbial contamination, proinflammatory effects, hepatosplenomegaly) are unlikely to be relevant in the manner that they are used for the treatment of LAST. A recent study calculated the lethal dose in 50% of test animals (LD 50 ) of Intralipid for bolus administration in rats (at 48 h) to be 67.7 ± 10.7 mL/kg. This represents an excellent safety profile, as many case reports describe a successful outcome well below the recommended upper limit of 10 mL/kg cumulative dose. However, the correct conversion for allometric scaling of this dose to a human is unknown. Furthermore, the LD 50 per se cannot be readily converted to a ''maximal safe'' or lowest toxic dose, and is therefore of limited use in determining a dosing limit for lipid emulsion. The efficacy of lipid emulsions in systemic bupivacaine toxicity is widely accepted by the medical community. However, there is some concern about the efficacy of lipid emulsion in systemic toxicity secondary to LAs that are less lipid soluble than bupivacaine. There is a theoretical basis for this argument and some supporting evidence from animal studies. In contrast, a growing number of case reports describe successful treatment of systemic toxicity from a variety of less lipid soluble LAs such as mepivacaine, ropivacaine, lidocaine, and prilocaine.
Zausig et al 13 tested this proposal in an isolated perfused heart model. After a standard preparation, 15 rat hearts were randomly assigned to receive equipotent doses of bupivacaine, ropivacaine, or mepivacaine until a 2-minute period of asystole is achieved. Addition of a lipid emulsion (Lipofundin MCT/LCT, 20% B. Braun, Melsungen, Germany) to the standard perfusate improved some recovery characteristics from bupivacaine-induced asystole. However, recovery was not facilitated in asystole secondary to ropivacaine or mepivacaine overdose. Several objections can be raised as to the applicability of these results to clinical practice. 18 One key objection is the suitability of this experimental model to studying the question posed. In contrast to in vivo cardiac arrest, coronary perfusion with oxygenated buffer solution was maintained (despite asystole) in this isolated heart model for the duration of the experiment. In the isolated perfused heart model, myocardial bupivacaine washout has been shown to occur even in the absence of lipid emulsions. Therefore, it is possible that the heart preparations in this study might have recovered from LA toxicity simply due to the buffer flow. As a result, there was not much additional room to demonstrate further benefit from the addition of lipid emulsion in this experimental model. More important, the lipid treatment was based on suggested ''per kg'' dosing from published clinical guidelines rather than a (weight:volume) percent of lipid or precise triglyceride concentration, and cannot be assumed to correlate with the lipid concentration exposed to the heart when lipid emulsion is given in a clinical setting. Even though the validity of the model could be accepted, the choice of lipid emulsion (Lipofundin, a formulation with mediumchain triglycerides) and the manner of administration (infusion without an initial bolus) is not comparable with the clinical experience.
Clinical Evidence Despite their limitations, case reports provide the best human evidence available. Some of these limitations lead to potential bias toward (i) reporting favorable outcomes, (ii) difficulty proving that lipid emulsion had a causative effect on the favorable outcomes, and (iii) variability in a number of factors (eg, type and dose of the LA, route of administration of the LA, symptoms observed, choice of lipid emulsion, timeframe of administration, dosing of the lipid emulsion, and definition of favorable outcome). With these in mind, there are nevertheless several case reports describing the use of lipid emulsions for treatment of LAST due to bupivacaine (Table 1 ) and other LAs (Table 2) including lidocaine.
Lipid Emulsion in Systemic Toxicity of Bupivacaine To date, there are 10 peer-reviewed case reports 12, 17, [19] [20] [21] [22] [23] [24] [25] 33 on the use of lipid emulsion in bupivacaine toxicity ( Table 1 ). All of these describe successful resolution of symptoms. The majority of these cases had seizures and loss of consciousness, followed by asystole, ventricular tachycardia, ventricular fibrillation (VF), or pulseless electrical activity. Before the administration of lipid emulsion, all the authors describe prompt attention to the airway, ventilation of the lungs with 100% oxygen in the apneic patient, chest compressions in the absence of pulses, and rapid electrical defibrillation when VF was diagnosed. One reported case is an infant, 23 whereas another is a 6-year-old patient with carnitine deficiency. 17 Finally, 3 of the reported cases occurred in octogenarians, 12, 21, 24 which highlight the effectiveness of lipid emulsion in reversing systemic bupivacaine toxicity in the extremes of age.
Lipid Emulsion in Toxicity of LAs Other Than Bupivacaine There are 7 peer-reviewed case reports describing the use of lipid emulsion in for nonbupivacaine-related LAST (Table 2) . [26] [27] [28] [29] [30] [31] [32] Six of 7 cases reported resolution of signs and symptoms of LAST with lipid infusion, whereas 1 case report 26 describe persistence of CNS symptoms despite 2 boluses of 20% lipid emulsion.
Ropivacaine was the sole LA in 3 reported cases of lipid emulsion reversing LAST, 29,31,32 2 of which resulted in asystole and the third in VF. These cases contradict the findings of Zausig et al. 13 One of the asystolic patients was given a 0.3 mg bolus of epinephrine followed by a 50 mL bolus of 20% Intralipid over a few seconds. 32 Sinus rhythm resumed ''at the end of (the lipid) infusion.'' The other case with asystole received 3 doses of 1 mg intravenous epinephrine over 10 minutes of ACLS before 100 mL of 20% Intralipid was bolused intravenously, and an infusion was started at 10 mL/min. 31 A cardiac rhythm with palpable pulses resumed at 10 minutes after the lipid bolus (after a total of 200 mL of 20% Intralipid was administered). The case with VF was converted to atrial fibrillation (the underlying rhythm) after 2 electrical defibrillations followed by lipid emulsion and amiodarone. 29 Levobupivacaine was responsible after a lumbar plexus block in 1 patient for seizures followed by severe hypotension and arrhythmias. 28 Electrocardiogram findings showed a gradual decrease in voltage with progressive widening of QRS complexes. Within 4 minutes of the event, 100 mL of 20% Intralipid was infused over 5 minutes. As the lipid emulsion was being administered, the authors describe a rapid normalization of the QRS morphology and improved hemodynamics. In fact, Update on the use of Lipid Emulsions ' 97 www.anesthesiaclinics.com the procedure (surgical repair of femur fracture) was performed as planned and the patient was discharged to the ward postoperatively in ''stable, oriented, and pain-free condition.'' 28 Mepivacaine toxicity was described in 2 cases, 27, 30 in which lipid emulsion was administered at the appearance of the CNS symptoms and may have averted progression to CV collapse. In 1 case, an axillary block with 50 mL of 2% mepivacaine resulted in dysarthria, myoclonus, and confusion in a 19-year-old patient. Bolus administration of 100 mL of a lipid emulsion promptly reversed these symptoms, and no CV toxicity was observed. Another case reported the development of CNS symptoms (dizziness and agitation, followed by loss of consciousness) with intermittent supraventricular extrasystoles and atrial bigeminy. Administration of 100 mL of a lipid emulsion resulted in return of consciousness, and arrhythmias resolved with addition of another 100 mL of lipid. Serial blood samples were obtained and revealed a 50% decrease in plasma mepivacaine levels within 20 minutes of the axillary block. This is several-fold faster than a previous study, in which 120 minutes were needed for plasma mepivacaine levels to decrease by 50% after an axillary block 34 This can be seen as a clinical evidence of a pharmacokinetic effect of lipid infusion on LAs.
In contrast to the case reports with successful outcomes, Aveline et al 26 report ineffectiveness of lipid emulsion in reversing CNS symptoms of LAST. Agitation, confusion, unresponsiveness followed by jerking motion of the extremities was observed 30 minutes after the injection of a lidocaine/ropivacaine mixture for sciatic block. Two 100 mL boluses of 20% Intralipid were given intravenously about 2 minutes apart without a resolution of these symptoms. General anesthesia was then induced and the patient was intubated. After about an hour, the patient awoke and was extubated with a normal neurological examination. There was no progression to CV toxicity for the duration of the event. Authors note that the patient was taking carbamazepine, which also binds to voltage-gated sodium channels, and could have led to a drug interaction to enhance the CNS toxicity of the LAs. As another explanation, the authors suggest that the apparent lack of efficacy of the lipid emulsion might be due to the low lipid solubility of lidocaine (when compared with other LA). Finally, the patient was intubated and mechanically ventilated only after the administration of the lipid emulsion. It should be noted that a spontaneously breathing patient with increased respiratory rate and normal oxygen saturation could still have manifested respiratory acidosis, which would explain the ineffectiveness of the lipid emulsion in this case (at least until the respiratory acidosis was corrected with controlled ventilation).
Conclusions The majority of case reports suggest that intravenous lipid emulsion is effective for reversing both CV and CNS toxicity due to LAST involving bupivacaine, and with other less-lipophilic LAs. Given the lack of clinical evidence for adverse reactions to lipid emulsion infusion, there is currently no rationale for withholding lipid emulsion until standard ACLS protocol is proven ineffective. Lipid emulsion should be administered as soon as systemic toxicity from any LA is suspected; this opinion is endorsed in a recent systematic review of lipid emulsion therapy. 35 
Lipid Infusion as a Part of ACLS: Interaction and Integration With Vasopressor Therapy
Cardiac arrest secondary to LAST has unique properties. LAST does not cause structural damage, but results in reversible changes such as decreased myocardial contractility and increased arrhythmogenicity. 36, 37 In the 2010 American Heart Association guidelines for CPR, ''cardiac arrest in special situations'' is mentioned as an entity where special treatments or procedures beyond those provided during standard basic life support or ACLS might be required. 38 We believe that LAST is indeed a ''special situation'' that deserves specific consideration, related to the integration of lipid emulsion among other accepted drug therapies in ACLS protocol. A review of the relevant available experimental and clinical data follows.
Animal Studies Animal studies on lipid emulsion in LAST are heterogeneous due to: (i) variability in species (rat, rabbit, dog, swine), (ii) method of cardiac arrest (intravenous injection of bupivacaine with or without apnea), (iii) choice and dosage of vasopressors (epinephrine, vasopressin), and/or (iv) the timing and dosage of the lipid emulsion. 39, 40 With those limitations in mind, the following points can be made: (1) Lipid emulsion alone was successful in reversing bupivacaineinduced cardiac arrest in dogs when ventilation with 100% oxygen was started at the time of arrest along with internal cardiac massage.
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(2) Lipid emulsion, compared with epinephrine, led to better rate pressure product, lower serum lactate levels, no pulmonary edema, and no ventricular arrhythmias at 10 minutes after bupivacaineinduced cardiac arrest in rats. 42 Ventilation with 100% oxygen and closed cardiac massage was performed continuously from the time of onset of cardiac arrest. (3) In pigs, cardiac arrest in hypoxic conditions after systemic bupivacaine toxicity was not reversed with lipid emulsion, as opposed to an epinephrine/vasopressin combination. 43 In this model, CPR was delayed until 1 minute after cardiac arrest occurred. (4) In pigs, adding lipid emulsion to a high-dose epinephrine (100(mg/ mL) and vasopressin (1.5 U/kg) combination was not useful during resuscitation for bupivacaine-induced cardiac arrest. 44 As a comparison, vasopressors doses in this study were approximately 7 times and 2.5 times the clinically recommended doses for epinephrine and vasopressin, respectively. (5) In rat, resuscitation with an epinephrine dose of 10mg/kg or higher impaired the effectiveness of lipid emulsions after bupivacaine induced cardiac arrest; addition of small doses of epinephrine (<10 mg/kg) to lipid resulted in a faster return of spontaneous circulation (ROSC), but a similar rate pressure product at 15 minutes. 45 (6) Lipid emulsion resulted in poorer ROSC after hypoxic cardiac arrest in rabbits. 46 (7) Clinically relevant decreases in pH impaired the affinity of bupivacaine and ropivacaine for lipid in vitro.
14 Clinical Experience of Lipid Emulsion in LAST In the first published case report by Rosenblatt et al, 22 lipid emulsion was administered only after standard ACLS protocol failed to result in ROSC. In subsequent case reports, there was a trend toward earlier administration of lipid (including reports of its use before any vasopressors were given in some cases). There was also a trend toward administering lipid emulsion at the earliest signs/symptoms of LAST (ie, during CNS manifestations before the occurrence of any CV toxicity).
There are 9 case reports of LAST with either asystole, or a nonperfusing rhythm (ie, ventricular tachycardia, VF, or pulseless electrical activity). 17, [19] [20] [21] [22] 24, [31] [32] [33] These reports can be classified in 2 groups in terms of the timing of lipid administration: late (after standard ACLS protocol tried up to 20 minutes without ROSC) and early (as a first-line therapy in the ACLS protocol). There are 4 reported cases (3 adults and 1 child) in the late administration group. 17, 22, 31, 33 During the resuscitation efforts, all 3 adult patients received a total of 3 mg epinephrine and 2 of these received 40 units of vasopressin in addition to epinephrine. Lipid emulsion was given after 10 to 20 minutes of ACLS, and sinus rhythm with peripheral pulses was reported within minutes of lipid administration in all 3 cases. The pediatric patient (6 y old, 24 kg) received an initial bolus of 0.2 mg epinephrine, which resumed sinus rhythm but the patient remained hypotensive requiring additional epinephrine administration. Blood pressure improved and epinephrine was stopped shortly after the lipid emulsion was given.
In 5 cases, lipid emulsion was given early in the resuscitation (within 2 to 3 minutes of the initiation of ACLS protocol). 20, 21, 24, 32 In 2 of these cases, 20, 21 lipid emulsion was given and sinus rhythm resumed before any vasopressors were administered. In the other 3 cases, 19, 24, 32 patients received a single dose of epinephrine (0.3 mg or 1 mg), before the lipid emulsion was given by bolus. Similarly, sinus rhythm with palpable pulses was restored in all cases without further need for vasopressors.
Conclusions There is experimental evidence and a growing body of clinical experience to suggest that early administration of lipid emulsion (along with effective CPR) in cases of LAST might restore spontaneous circulation without the use of large doses of vasopressors. If lipid emulsion is not readily available, then standard ACLS protocol should be instituted, but lipid emulsion should be given as soon as it is available. However, withholding lipid emulsion (until vasopressors are ineffective) is not justified, based on current case report evidence and bench science authentication.
Experimental data suggest that high doses of vasopressors (epinephrine, vasopressin) decrease the effectiveness of lipid emulsion in LAST. 44, 45 Smaller doses of epinephrine (ie, <10 mg/mL) can be considered. Nevertheless, lipid emulsion was still successful in rapidly achieving ROSC in clinical case reports adhering to standard ACLS doses of epinephrine (1 mg) and vasopressin (40 units) . Maintaining oxygenation and ventilation of the lungs is crucial for the success of lipid emulsion boluses and infusions. Experimental data has shown that hypoxic cardiac arrest is refractory to the beneficial effects of lipid emulsion. 43, 46 This may be a direct effect of hypoxia, and/or due to the associated respiratory acidosis. Review of case reports also suggests that the clinical effect of lipid emulsion should be evident within 1 to 2 minutes of the initial bolus. This observation supports the current recommendation of 2 additional doses (5 min apart), if there is no ROSC with the first dose of lipid emulsion.
As of 2011, our goal should be to make LAST an avoidable or treatable condition. Intravenous lipid emulsion is a powerful tool in achieving this goal. Many aspects in the clinical use of lipid emulsion are evolving. Nevertheless, a framework (based on the evidence reviewed in this article) to build refinements now exists. 
